Learning Objectives
Upon completion of this activity, participants should be able to:
- Interpret new data on the utilization of lung cancer screening methods to improve outcomes for patients with early-stage non-small-cell lung cancer
- Apply recent findings on available treatment modalities to improve the clinical management of patients with early-stage non-small-cell lung cancer
- Evaluate the predictive and prognostic value of clinical characteristics and putative biomarkers for early-stage non-small-cell lung cancer
Topics covered include:
- National Lung Screening Trial: Screening by CT Scan vs Chest X-Ray
- Biomarker Status of p27, p16, Cyclin E, and Bax in Early-Stage Resected NSCLC
- Prognostic Value of a Novel 6-Gene Transcriptional Signature in Early-Stage NSCLC
- GI-4000 Vaccine as Consolidation Therapy in KRAS-Mutant NSCLC Patients
- Prognosis With PET vs Histologic Staging of Mediastinum in N0-1 NSCLC
- Effect of Tumor Size on Benefit of Adjuvant Chemotherapy in N0 NSCLC
- Prognostic Strength of Microscopic Vascular Invasion vs T Size in NSCLC
- Comparison of VATS Lobectomy vs Thoracotomy Lobectomy for NSCLC
- Efficacy of Stereotactic Body Radiation Therapy in Operable T1N0M0 NSCLC
- SBRT in Patients With Stage I NSCLC and Severe Chronic Obstructive Pulmonary Disease
- SBRT vs Surgery in Elderly Patients With Stage I NSCLC